Project List
List projects.
Fields
id (integer)
Primary key.
Expansions
To activate relation expansion add the desired fields as a comma separated
list to the expand query parameter like this:
?expand=<field>,<field>,<field>,...
The following relational fields can be expanded:
organizationcategorytypepartner_functionmanagercontactstatusgrantresearcheventstudylanguageprogramfunders
Filters
To filter for exact value matches:
?<fieldname>=<value>
Possible exact filters:
organizationcategorymanagercontactstatusgrantresearchstudylanguagefundersprogram
For advanced filtering use lookups:
?<fieldname>__<lookup>=<value>
All fields with advanced lookups can also be used for exact value matches as described above.
Possible advanced lookups:
begin_planned:gt,gte,lt,ltebegin_effective:gt,gte,lt,lteend_planned:gt,gte,lt,lteend_effective:gt,gte,lt,lte
GET /v1/research/project/?format=api&ordering=-end_effective
{ "count": 2242, "next": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=20&ordering=-end_effective", "previous": null, "results": [ { "id": 292, "title": { "de": "AT-0042 Image Processing, Information Engineering & Interdisciplinary Knowledge Exchange", "en": "AT-0042 Image Processing, Information Engineering & Interdisciplinary Knowledge Exchange" }, "short": "CEEPUS-Netzwerk AT-0042", "url": null, "abstract": { "de": "Virtual Endoscopy of Airways: \r\nApplying methods of virtual reality to Spiral Computed Tomography investigations of airways, views can be generated similar to endoscopy . These views can be used to simulate endoscopic procedures for training of residents or for planing therapeutic interventions. Moreover, the virtual camera can be sent to positions, where a real endoscope fails.\r\n\r\nVirtual Dissection of the Colon: \r\nBesides endoscopy different imaging strategies are available for detection of colonic polyps. The medical goals is to detect those polyps as early as possible in order to prevent the development of a colonic cancer. Spiral Computed Tomography (S-CT) and Magnetic Resonance Tomography (MRT), augmented by virtual reality, have already demonstrated their effectivness in the detection of colonic polyps.\r\n\r\nComputer Aided Diagnosis of Breast Cancer:\r\nA system was programmed to support the reporting radiologist as a \"never tied second reader\" by using algorithms of artificial neural nets and image processing. In addition, a graphical user interface was developed to display the results of the \"never tired second reader\" to the radiologist in a convenient way. \r\n\r\n", "en": "Virtual Endoscopy of Airways: \r\nApplying methods of virtual reality to Spiral Computed Tomography investigations of airways, views can be generated similar to endoscopy . These views can be used to simulate endoscopic procedures for training of residents or for planing therapeutic interventions. Moreover, the virtual camera can be sent to positions, where a real endoscope fails.\r\n\r\nVirtual Dissection of the Colon: \r\nBesides endoscopy different imaging strategies are available for detection of colonic polyps. The medical goals is to detect those polyps as early as possible in order to prevent the development of a colonic cancer. Spiral Computed Tomography (S-CT) and Magnetic Resonance Tomography (MRT), augmented by virtual reality, have already demonstrated their effectivness in the detection of colonic polyps.\r\n\r\nComputer Aided Diagnosis of Breast Cancer:\r\nA system was programmed to support the reporting radiologist as a \"never tied second reader\" by using algorithms of artificial neural nets and image processing. In addition, a graphical user interface was developed to display the results of the \"never tired second reader\" to the radiologist in a convenient way. \r\n\r\n" }, "begin_planned": null, "begin_effective": "1997-01-01T01:00:00+01:00", "end_planned": null, "end_effective": "2050-12-31T01:00:00+01:00", "assignment": "2005-10-26T02:00:00+02:00", "program": null, "subprogram": null, "organization": 14106, "category": 10, "type": 10, "partner_function": 2, "manager": 51913, "contact": 51913, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "292-51913-10" ] }, { "id": 9477, "title": { "de": "NeuroVitalizer: Entschlüsselung multimodaler TBI-Marker für eine optimierte Genesung", "en": "NeuroVitalizer: Decoding multimodal TBI markers for optimized recovery" }, "short": "NeuroVitalizer", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2026-01-02T01:00:00+01:00", "begin_effective": "2026-01-01T01:00:00+01:00", "end_planned": "2031-01-31T01:00:00+01:00", "end_effective": "2030-12-31T01:00:00+01:00", "assignment": "2025-12-11T16:14:44+01:00", "program": 208, "subprogram": null, "organization": 14050, "category": 10, "type": 10, "partner_function": 2, "manager": 72095, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 10 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "9477-72095-10" ] }, { "id": 9208, "title": { "de": "Entwicklung von PNPLA3 Inhibitoren", "en": "Targeting PNPLA3 activity to elucidate its role in MASLD" }, "short": "PNPLA3 Inhibitoren", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2025-10-01T02:00:00+02:00", "begin_effective": "2026-01-01T01:00:00+01:00", "end_planned": "2030-09-30T02:00:00+02:00", "end_effective": "2030-12-31T01:00:00+01:00", "assignment": "2025-09-18T13:18:49+02:00", "program": 250, "subprogram": null, "organization": 14013, "category": 10, "type": 10, "partner_function": 4, "manager": 124190, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "AST7750924", "ethics_committee": null, "edudract_number": null, "persons": [ "9208-124190-10" ] }, { "id": 8728, "title": { "de": "Vergleich der konvektive Wasserdampfablation (convective water vapor energy, WAVE™)\r\nmit dem Rezum™-System versus Holmium Laser Enukleation der Prostata (HoLEP) versus\r\nbipolare transurethrale Resektion der Prostata (TUR-P) bei Patienten mit benignen\r\nProstatasyndrom (BPS) – eine randomisierte Studie", "en": "Comparison of Convective Water Vapor Ablation (convective water vapor energy, WAVE™)\r\nwith the Rezum™ System versus Holmium Laser Enucleation of the Prostate (HoLEP) versus\r\nBipolar Transurethral Resection of the Prostate (TUR-P) in Patients with Benign Prostatic\r\nSyndrome (BPS) – A Randomized Study" }, "short": "Vektor", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2025-01-01T01:00:00+01:00", "begin_effective": "2025-01-01T01:00:00+01:00", "end_planned": "2030-12-31T01:00:00+01:00", "end_effective": "2030-12-31T01:00:00+01:00", "assignment": "2025-03-17T15:43:09+01:00", "program": null, "subprogram": null, "organization": 14056, "category": 10, "type": 10, "partner_function": 3, "manager": 121670, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": 12, "language": null, "funders": [], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "8728-121670-10" ] }, { "id": 9279, "title": { "de": "Verständnis und Kontrolle von Methanobrevibacter zum Nutzen von Umwelt und Gesundheit", "en": "Archaeal keystone species in host microbiomes:\r\nUnderstanding and controlling Methanobrevibacter for Environmental and Health Benefits" }, "short": "ARCH-Meth", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2025-10-01T02:00:00+02:00", "begin_effective": "2026-01-01T01:00:00+01:00", "end_planned": "2030-09-30T02:00:00+02:00", "end_effective": "2030-12-31T01:00:00+01:00", "assignment": "2025-10-30T09:03:41+01:00", "program": 208, "subprogram": null, "organization": 14023, "category": 10, "type": 10, "partner_function": 4, "manager": 90021, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 10 ], "funder_projectcode": "101199346", "ethics_committee": null, "edudract_number": null, "persons": [ "9279-90021-10" ] }, { "id": 9014, "title": { "de": "Elemental and Structural Composition underlying Brain MRI", "en": "Elemental and Structural Composition underlying Brain MRI" }, "short": "WhatsMRI", "url": null, "abstract": { "de": "Magnetic Resonance Imaging (MRI) is widely established, with 50,000 scanners worldwide and more than100 million diagnostic scans conducted yearly. Myelin acts as the electrical insulation of neuronal fibers andis essential for motor, sensory, and cognitive functions and is composed of several lipids and proteins arrangedin a specific geometry. However, myelin loss occurs regionally in inflammatory diseases like multiplesclerosis, myelitis, and optic neuritis, and it also serves as a biomarker of aging.Despite the availability of various MRI-based approaches for detecting myelin, there remains a significant gapin systematically validated knowledge regarding how myelin's lipids, proteins, and structural variationsinfluence MRI signal generation. Furthermore, there is no gold standard for assessing the constituents ofmyelin, and conclusions are primarily based on MRI of formalin-fixed tissue.Quantitative post-mortem MRI of unfixed human brains in situ, combined with subsequent mass spectrometryimaging (LA-ICP-TOF-MS, MALDI-MSI), small-angle X-ray scattering (SAXS), and microscopy (CARS,TEM, IHC), will enable histologically enriched modelling of tissue and the simulation of fundamental MRIparameters (relaxometry, susceptibility, and diffusion) to reveal causal relationships with chemical elements,matrix composition, structure, and common molecules of myelin, neural fiber orientation, and biometals. Inaddition to 20 control brains, 10 brains from deceased individuals with multiple sclerosis will be recruited tobroaden the spectrum of myelination under investigation.This research addresses the fundamental biophysical mechanisms underlying MRI of myelin and chemicalelements, which currently lack validation. We will establish a publicly available elemental and histochemicalatlas of the human brain and identify how histological features causally contribute to quantitative MRIparameters.", "en": "Magnetic Resonance Imaging (MRI) is widely established, with 50,000 scanners worldwide and more than100 million diagnostic scans conducted yearly. Myelin acts as the electrical insulation of neuronal fibers andis essential for motor, sensory, and cognitive functions and is composed of several lipids and proteins arrangedin a specific geometry. However, myelin loss occurs regionally in inflammatory diseases like multiplesclerosis, myelitis, and optic neuritis, and it also serves as a biomarker of aging.Despite the availability of various MRI-based approaches for detecting myelin, there remains a significant gapin systematically validated knowledge regarding how myelin's lipids, proteins, and structural variationsinfluence MRI signal generation. Furthermore, there is no gold standard for assessing the constituents ofmyelin, and conclusions are primarily based on MRI of formalin-fixed tissue.Quantitative post-mortem MRI of unfixed human brains in situ, combined with subsequent mass spectrometryimaging (LA-ICP-TOF-MS, MALDI-MSI), small-angle X-ray scattering (SAXS), and microscopy (CARS,TEM, IHC), will enable histologically enriched modelling of tissue and the simulation of fundamental MRIparameters (relaxometry, susceptibility, and diffusion) to reveal causal relationships with chemical elements,matrix composition, structure, and common molecules of myelin, neural fiber orientation, and biometals. Inaddition to 20 control brains, 10 brains from deceased individuals with multiple sclerosis will be recruited tobroaden the spectrum of myelination under investigation.This research addresses the fundamental biophysical mechanisms underlying MRI of myelin and chemicalelements, which currently lack validation. We will establish a publicly available elemental and histochemicalatlas of the human brain and identify how histological features causally contribute to quantitative MRIparameters." }, "begin_planned": "2025-01-01T01:00:00+01:00", "begin_effective": "2025-10-01T02:00:00+02:00", "end_planned": "2030-01-01T01:00:00+01:00", "end_effective": "2030-09-30T02:00:00+02:00", "assignment": "2025-06-10T15:39:19+02:00", "program": 208, "subprogram": null, "organization": 14051, "category": 10, "type": 10, "partner_function": 3, "manager": 60116, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 10 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "9014-70759-11", "9014-86408-11", "9014-101162-11", "9014-60116-10", "9014-132017-12", "9014-134821-12", "9014-135321-12", "9014-135543-12", "9014-127954-12" ] }, { "id": 9562, "title": { "de": "TRP-vermittelte Kationen Signalwege TRPC.at", "en": "TRP-dependentCation signalling TRPC.at" }, "short": "TRPC.at", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2026-03-01T01:00:00+01:00", "begin_effective": "2026-10-01T02:00:00+02:00", "end_planned": "2029-02-27T01:00:00+01:00", "end_effective": "2030-09-30T02:00:00+02:00", "assignment": "2026-01-27T15:00:59+01:00", "program": 114, "subprogram": null, "organization": 14011, "category": 10, "type": 10, "partner_function": 3, "manager": 98848, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "DOC4380225", "ethics_committee": null, "edudract_number": null, "persons": [ "9562-98848-10" ] }, { "id": 8079, "title": { "de": "Wirkmechanismus von Mikroplastik in entzündlichen Darmerkrankungen", "en": "Action of microplastic in inflammatory bowel diseases" }, "short": null, "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2024-03-01T01:00:00+01:00", "begin_effective": "2024-03-01T01:00:00+01:00", "end_planned": "2030-03-01T01:00:00+01:00", "end_effective": "2030-03-01T01:00:00+01:00", "assignment": "2024-03-11T14:44:13+01:00", "program": null, "subprogram": null, "organization": 17230, "category": 10, "type": 10, "partner_function": 4, "manager": 87298, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 1743 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "8079-87298-10" ] }, { "id": 9380, "title": { "de": "Studie zur Evaluierung der Effektivität von kontinuierlichem Glukosemonitoring bei Menschen mit neudiagnostiziertem Typ 2 Diabetes", "en": "A Trial To evaluate the Efficacy of continuous glucose monitoring as add oN Therapy In peOple with Newly diagnosed Type 2 Diabetes" }, "short": "ATTENTION-T2D", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2026-02-01T01:00:00+01:00", "begin_effective": "2026-02-01T01:00:00+01:00", "end_planned": "2030-01-30T01:00:00+01:00", "end_effective": "2030-01-30T01:00:00+01:00", "assignment": "2025-11-11T14:21:16+01:00", "program": 253, "subprogram": null, "organization": 14080, "category": 10, "type": 10, "partner_function": 3, "manager": 50838, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "KIN2903525", "ethics_committee": null, "edudract_number": null, "persons": [ "9380-50838-10" ] }, { "id": 9490, "title": { "de": "Dynamik von lipid-asoz. Makrophagen bei Gewichtsregulierung", "en": "LAM dynamics during weight cycling" }, "short": null, "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2026-01-01T01:00:00+01:00", "begin_effective": "2026-01-07T01:00:00+01:00", "end_planned": "2029-12-31T01:00:00+01:00", "end_effective": "2030-01-06T01:00:00+01:00", "assignment": "2025-12-16T11:37:36+01:00", "program": 72, "subprogram": null, "organization": 14017, "category": 10, "type": 10, "partner_function": 4, "manager": 89979, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "PAT1140225", "ethics_committee": null, "edudract_number": null, "persons": [ "9490-89979-10" ] }, { "id": 8362, "title": { "de": "MEK Inhibition bei RAS-mutierter/EZH2-inaktivierter CMML", "en": "MEK inhibition in RAS-mutated/EZH2-inactivated CMML" }, "short": null, "url": null, "abstract": { "de": "Forschungskontext/theoretischer Rahmen:\r\nDie chronische myelomonozytäre Leukämie (CMML) ist eine aggressive hämatopoetische Neoplasie, die häufig auf Aberrationen zurückzuführen ist, die die RAS-Onkogene verändern (RASmut). Leider sind die derzeitigen therapeutischen Ansätze für RASmut-CMML-Patienten unzureichend. Wir zeigen, dass RASmut bei CMML häufig mit inaktivierenden Aberrationen des epigenetischen Modifikators EZH2 (EZH2inact) einhergeht. In-vitro-Zellkulturstudien zeigen, dass myeloische Zellen mit RASmut/EZH2inact eine Hyperaktivierung der RAS-Signaltransduktion aufweisen und besonders stark auf eine RAS-MAPK/ERK-Inhibition mit MEK-Inhibitoren (MEKi) reagieren.\r\n\r\nHypothesen/Forschungsfragen/Zielsetzungen:\r\nForschungsfrage: \r\nWir fragen, ob unterschiedliche pharmakologische Ansätze therapeutisch auf RASmut/EZH2inact CMML abzielen können.\r\nHypothese: \r\nWir stellen die Hypothese auf, dass RASmut und EZH2inact synergistisch RAS-Signalwege in CMML aktivieren und eine erhöhte Empfindlichkeit gegenüber MEKi verleihen.\r\nZielsetzungen: \r\nDurch die strategische Einbindung unserer Biobank mit klinisch gut annotierten Patientenproben in modernste In-vitro- und In-vivo-Ansätze werden wir zunächst unser Wissen über die Auswirkungen des gemeinsamen Auftretens von RASmut/EZH2inact auf die RAS-MAPK/ERK-Signalübertragung bei CMML erweitern. Anschließend werden wir die MEKi-Therapie in diesen Modellen analysieren und nach einer bevorzugten Empfindlichkeit des RASmut/EZH2inact-Genotyps fragen. Schließlich werden wir die Auswirkungen von MEKi auf RASmut/EZH2inact CMML-Leukämie-Stammzellen (LSC) und die klonale Evolution untersuchen. \r\n\r\nHerangehensweise/Methoden:\r\nWir werden zunächst die Auswirkungen von EZH2inact auf die Aktivierung der RASmut-Signalübertragung in transgenen In-vivo-Mausmodellen, primären CMML-Patientenproben und von Patienten stammenden Xenografts (PDX) untersuchen. Diese Analysen werden die durchflusszytometrische Bewertung des RAS-signalisings in hämatopoetischen Stamm- und Vorläuferzellen (HSPC) und LSC umfassen. Anschließend werden wir diese Modelle verwenden, um die Auswirkungen des gleichzeitigen Auftretens von RASmut/EZH2inact auf MEKi zu bewerten. Letztendlich wollen wir das therapeutische Potenzial von MEKi zur Heilung von RASmut/EZH2inact CMML bewerten. Daher werden wir die Auswirkungen der MEKi-Behandlung auf RASmut/EZH2inact-HSPC-Kompartimente, CMML-LSC und die klonale Evolution der CMML untersuchen. \r\n\r\nGrad der Originalität/Innovation:\r\nDie gezielte Beeinflussung der aberranten RAS-Signalübertragung ist seit Jahrzehnten ein wichtiger Forschungsschwerpunkt. Obwohl seit kurzem direkte RAS-Inhibitoren der nächsten Generation zur Verfügung stehen, war der therapeutische Nutzen für RASmut-CMML-Patienten begrenzt. Dieses Projekt untersucht einen neuartigen Ansatz und schlägt vor, dass eine erfolgreiche molekular gesteuerte Behandlung bei RASmut CMML den Einfluss von koexistierenden und funktionell interagierenden Läsionen berücksichtigen muss.\r\n\r\nBeteiligte Hauptforscher:\r\nArmin Zebisch, der über eine langjährige Erfahrung auf dem Gebiet der RAS-Signalübertragung bei myeloischen Neoplasien verfügt, wird der Hauptforscher sein. Er wird von klinischen Hämatologen und Grundlagenforschern unterstützt, die über profunde Kenntnisse der CMML und der in diesem Projekt verwendeten Modelle verfügen. Ein Doktorand und ein Techniker werden sein Laborteam bei der Durchführung dieses Projekts unterstützen.\r\n", "en": "Wider research context/theoretical framework:\r\nChronic myelomonocytic leukemia (CMML) is an aggressive hematopoietic neoplasia and is frequently driven by aberrations modifying the RAS oncogenes (RASmut). Unfortunately, current therapeutic approaches for RASmut CMML patients are insufficient. We demonstrate that RASmut in CMML often co-occur with inactivating aberrations of the epigenetic modifier EZH2 (EZH2inact). In-vitro cell culture studies reveal that RASmut/EZH2inact myeloid cells exhibit RAS-signaling hyperactivation and might be preferentially sensitive to RAS-MAPK/ERK inhibition with MEK inhibitors (MEKi).\r\n\r\nHypotheses/research questions/objectives:\r\nResearch question: \r\nWe ask whether distinctive pharmacological approaches can therapeutically target RASmut/EZH2inact CMML.\r\nHypothesis:\r\nWe hypothesize that RASmut and EZH2inact synergistically activate RAS-signaling pathways in CMML and confer increased sensitivity to MEKi.\r\nObjectives: \r\nBy strategically incorporating our biobank with clinically well-annotated patient specimens into state-of-the-art in-vitro and in-vivo approaches, we will initially extend our knowledge on the effects of RASmut/EZH2inact co-occurrence on RAS-MAPK/ERK signaling in CMML. We will then analyze MEKi therapy within these models and ask for preferential sensitivity in the RASmut/EZH2inact genotype. Ultimately, we will assess the effects of MEKi on RASmut/EZH2inact CMML-leukemic stem cells (LSC) and clonal evolution. \r\n\r\nApproach/methods:\r\nWe will initially elaborate on the effects of EZH2inact on the activation of RASmut-signaling in transgenic murine in-vivo models, primary CMML patient specimens, and patient-derived xenografts (PDX). These analyses will include the flow-cytometry-based assessment of RAS-signaling in hematopoietic stem and progenitor cells (HSPC) and LSC. We will then use these models to assess the effects of RASmut/EZH2inact co-occurrence on MEKi. Ultimately, we will aim to assess the therapeutic potential of MEKi to cure RASmut/EZH2inact CMML. Therefore, we will study the effects of MEKi treatment on RASmut/EZH2inact HSPC compartments, CMML-LSC and clonal evolution of CMML. \r\nLevel of originality/innovation\r\nTargeting aberrant RAS signaling has been a significant focus of research for the last decades. Despite the recent advent of direct next-generation RAS inhibitors, the therapeutic benefit for RASmut CMML patients was limited. This project assesses a novel approach and proposes that successful molecular-guided treatment in RASmut CMML must consider the influence of co-existing and functionally interacting lesions.\r\nPrimary researchers involved\r\nArmin Zebisch has a strong track record on RAS-signaling in myeloid neoplasms and will be the principal investigator. He will be supported by clinical hematologists and basic researchers with profound expertise in CMML and the models used within this project. A PhD student and technician will further support his lab team in executing this project.\r\n" }, "begin_planned": "2025-01-01T01:00:00+01:00", "begin_effective": "2025-01-01T01:00:00+01:00", "end_planned": "2028-01-01T01:00:00+01:00", "end_effective": "2029-12-31T01:00:00+01:00", "assignment": "2024-08-21T15:56:58+02:00", "program": 72, "subprogram": null, "organization": 14082, "category": 10, "type": 10, "partner_function": 4, "manager": 57402, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "PAT 1753824", "ethics_committee": null, "edudract_number": null, "persons": [ "8362-57402-10", "8362-97430-12", "8362-97983-12", "8362-50116-12" ] }, { "id": 9536, "title": { "de": "Multimodale Strategien zur Bewältigung der wichtigsten Herausforderungen bei Blasenkrebs", "en": "Multimodal Strategies to Target Key Challenges in Bladder Cancer" }, "short": "StrikeBC", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2026-01-01T01:00:00+01:00", "begin_effective": "2026-01-01T01:00:00+01:00", "end_planned": "2033-12-31T01:00:00+01:00", "end_effective": "2029-12-31T01:00:00+01:00", "assignment": "2026-01-16T16:21:22+01:00", "program": 251, "subprogram": null, "organization": 14021, "category": 10, "type": 10, "partner_function": 2, "manager": 50899, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 19 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "9536-50899-10" ] }, { "id": 9535, "title": { "de": "Multimodale Strategien zur Behandlung von Harnblasenkrebs", "en": "Multimodal Strategies to Target Key Challenges in Bladder Cancer" }, "short": "StrikeBC", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2026-01-02T01:00:00+01:00", "begin_effective": "2026-01-01T01:00:00+01:00", "end_planned": "2033-12-31T01:00:00+01:00", "end_effective": "2029-12-31T01:00:00+01:00", "assignment": "2026-01-16T16:12:05+01:00", "program": 251, "subprogram": null, "organization": 14085, "category": 10, "type": 10, "partner_function": 2, "manager": 86226, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 19 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "9535-86226-10" ] }, { "id": 9537, "title": { "de": "Multimodale Strategien zur Bewältigung der wichtigsten Herausforderungen bei Blasenkrebs\r\n", "en": "Multimodal Strategies to Target Key Challenges in Bladder Cancer" }, "short": "StrikeBC", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2026-01-01T01:00:00+01:00", "begin_effective": "2026-01-01T01:00:00+01:00", "end_planned": "2029-12-31T01:00:00+01:00", "end_effective": "2029-12-31T01:00:00+01:00", "assignment": "2026-01-16T16:32:15+01:00", "program": 251, "subprogram": null, "organization": 14056, "category": 10, "type": 10, "partner_function": 4, "manager": 113095, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 19 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "9537-113095-10" ] }, { "id": 8299, "title": { "de": "Energetik-Transkriptions Kopplung im hypertensiven Herzen", "en": "Energetics-transcription coupling in hypertensive heart" }, "short": null, "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2025-01-01T01:00:00+01:00", "begin_effective": "2025-01-01T01:00:00+01:00", "end_planned": "2029-12-31T01:00:00+01:00", "end_effective": "2029-12-31T01:00:00+01:00", "assignment": "2024-07-17T18:19:55+02:00", "program": 110, "subprogram": null, "organization": 14083, "category": 10, "type": 10, "partner_function": 4, "manager": 62747, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "STA 194", "ethics_committee": null, "edudract_number": null, "persons": [ "8299-62747-10", "8299-75758-12", "8299-105142-12", "8299-110709-12", "8299-117943-12", "8299-131037-12", "8299-122231-12" ] }, { "id": 9223, "title": { "de": "Diethylsuccinat als neues Therapeutikum bei IPF", "en": "Diethylsuccinate as a novel therapeutic for IPF" }, "short": "Diethylsuccinat_therapeutic_IPF", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2025-10-01T02:00:00+02:00", "begin_effective": "2025-11-01T01:00:00+01:00", "end_planned": "2028-09-30T02:00:00+02:00", "end_effective": "2029-10-31T01:00:00+01:00", "assignment": "2025-09-24T11:54:15+02:00", "program": 72, "subprogram": null, "organization": 14022, "category": 10, "type": 10, "partner_function": 4, "manager": 85658, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "PAT2165825", "ethics_committee": null, "edudract_number": null, "persons": [ "9223-85658-10", "9223-50132-12", "9223-111587-12", "9223-116746-12", "9223-126994-12" ] }, { "id": 9298, "title": { "de": "BioTransform: Mapping des unbekannten menschlichen Stoffwechsels neuer biologischer Wirkstoffe in Lebensmitteln\r\n\r\n\r\n\r\n", "en": "BioTransform: Mapping the unchartered human metabolism for novel food bioactives\r\n" }, "short": "BioTransform", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2023-10-01T02:00:00+02:00", "begin_effective": "2025-11-01T01:00:00+01:00", "end_planned": "2027-09-30T02:00:00+02:00", "end_effective": "2029-10-31T01:00:00+01:00", "assignment": "2025-11-05T15:18:11+01:00", "program": 209, "subprogram": null, "organization": 14014, "category": 10, "type": 10, "partner_function": 2, "manager": 51266, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "9298-51266-10", "9298-88711-11" ] }, { "id": 8527, "title": { "de": "Metabolische Kontrolle von Altern und Krankheit", "en": "Metabolic control of aging and disease" }, "short": "MetAGE", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2024-10-01T02:00:00+02:00", "begin_effective": "2024-10-01T02:00:00+02:00", "end_planned": "2029-09-30T02:00:00+02:00", "end_effective": "2029-09-30T02:00:00+02:00", "assignment": "2024-11-21T16:24:26+01:00", "program": 125, "subprogram": null, "organization": 14012, "category": 10, "type": 10, "partner_function": 2, "manager": 91207, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "COE14", "ethics_committee": null, "edudract_number": null, "persons": [ "8527-91207-10", "8527-50360-12", "8527-97044-12", "8527-50119-12", "8527-108411-12", "8527-122011-12", "8527-125854-12", "8527-129219-12", "8527-127057-12" ] }, { "id": 8525, "title": { "de": "Metabolische Kontrolle von Altern und Krankheit", "en": "Metabolic control of aging and disease" }, "short": "MetAGE", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2023-10-01T02:00:00+02:00", "begin_effective": "2024-10-01T02:00:00+02:00", "end_planned": "2028-09-30T02:00:00+02:00", "end_effective": "2029-09-30T02:00:00+02:00", "assignment": "2024-11-21T16:12:41+01:00", "program": 125, "subprogram": null, "organization": 14013, "category": 10, "type": 10, "partner_function": 4, "manager": 51860, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "COE14", "ethics_committee": null, "edudract_number": null, "persons": [ "8525-70922-12", "8525-51860-10", "8525-120872-12", "8525-131699-12", "8525-124053-12", "8525-126655-12" ] }, { "id": 8526, "title": { "de": "Metabolische Kontrolle von Altern und Krankheit", "en": "Metabolic control of aging and disease" }, "short": "MetAGE", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2023-10-01T02:00:00+02:00", "begin_effective": "2024-10-01T02:00:00+02:00", "end_planned": "2028-09-30T02:00:00+02:00", "end_effective": "2029-09-30T02:00:00+02:00", "assignment": "2024-11-21T16:12:55+01:00", "program": 125, "subprogram": null, "organization": 14022, "category": 10, "type": 10, "partner_function": 4, "manager": 71487, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "COE14", "ethics_committee": null, "edudract_number": null, "persons": [ "8526-71487-10", "8526-116490-12", "8526-119268-12", "8526-125934-12", "8526-127474-12" ] } ] }